HIVREMITNCT07329166
Reducing Mobility-associated Interruption in HIV Treatment in Malawi
A study testing REMIT intervention package in people with HIV, run by University of California, Los Angeles at 1 site in Malawi.
Trial summary
The goal of this pilot clinical trial is to assess the feasibility and acceptability of an intervention package designed to reduce mobility-associated interruptions in HIV treatment in people living with HIV in Malawi who are initiating or returning to antiretroviral treatment (ART) after interruption. Read more about this study
- Who is it for?
- Ages 15 years and older
- Conditions the study is for
- HIV
- What is being tested?
- REMIT intervention package
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 1 siteMalawi
- Study dates
- 18 Dec 2025to Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- 15 years of age or older
- Living with HIV
- Attending ART clinic to initiate OR re-initiate care:
- Initiate: initiating ART for the first time, per self-report
- Re-initiate: returning to care after missing a refill appointment by >28 days
Who cannot join
- Attending ART clinic on behalf of someone else (i.e. guardian)
- Attending ART clinic only to obtain emergency refill
- Attending ART clinic for a routine refill without a recent >=28 days interruption in treatment
- Transferring in to study facility without a preceding interruption in treatment of >=28 days
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Malawi1 site, 1 recruiting
- Recruiting
Partners in Hope
Lilongwe
Eric Lungu, +265 999 292 486, eric@pihmalawi.com
Khumbo Phiri, MPH, +265 999 840 946, khumbo@pihmalawi.com
About this study
Official title: Reducing Mobility-associated Interruption in HIV Treatment in Malawi (REMIT): Pilot Trial to Assess Acceptability and Feasibility of a Mobility-specific Intervention Package
The goal of this pilot clinical trial is to assess the feasibility and acceptability of an intervention package designed to reduce mobility-associated interruptions in HIV treatment in people living with HIV in Malawi who are initiating or returning to antiretroviral treatment (ART) after interruption. The main questions it aims to answer are:
- Is the intervention acceptable to healthcare workers and ART clients?
- Is the intervention feasible in the context of Malawi's health system, and what are the major operational challenges, resource requirements, and implementation barriers?
Read more
In addition, researchers will compare HIV treatment outcomes (specifically ART retention rates) between intervention and control groups to establish a preliminary estimate of the intervention's efficacy.
Participants will complete a survey on the day of enrollment and some participants will complete an in-depth interview and/or a survey after completion of the 6-month follow-up period. Facilities assigned to the intervention group will receive the full package of interventions (training on mobility-specific counseling for counsellors, access to a toll-free hotline for clients and healthcare workers, and training on multi-month dispensing for providers), while facilities assigned to the control group will provide standard of care.
Read the detailed description
RATIONALE FOR RESEARCH: While Malawi has made tremendous progress towards ending the HIV epidemic - nearly reaching UNAIDS' 95-95-95 target goals (95% of people living with HIV know their status, 95% of people living with HIV have initiated ART, and 95% of those on ART reach viral suppression) - certain sub-groups of people living with HIV continue to face challenges remaining in care. One key issue that perpetuates this cycle of interruption, re-initiation, and re-interruption is mobility, or temporary travel, which is the number one reason for interruption in treatment (IIT) across several of our recent studies. Mobile people living with HIV require additional interventions to stay in care and reduce IIT. In the REMIT study (Reducing Mobility-associated Interruption in HIV Treatment), we will pilot a package of interventions that have been co-created with ART clients, healthcare workers (HCWs), and community and national stakeholders. The REMIT intervention package will include: enhanced counselling at initiation or re-initiation; a toll-free line for mobile clients and HCWs; and trainings for HCWs on the benefits of multi-month dispensing (MMD).
Study design and rationale: We propose a cluster-randomized control trial to pilot these interventions at three facilities, comparing results with three control facilities (total n=6 facilities). This cluster-randomized design is appropriate for testing interventions that are offered to healthcare workers (specifically training on an enhanced counselling curriculum and the benefits of MMD); each intervention facility will receive the full intervention package.
Population: The study population will include ART clients (≥15 years) who are initiating or re-initiating ART >28 days after a missed appointment. We will enrol n=400 men and women attending ART clinic for their own care.
We will randomly select a subset of participants from intervention facilities for additional in-depth interviews. We will also conduct focus group discussions with healthcare workers working in the ART clinic at intervention facilities.
People living with HIV and health care providers will be included in the study. Participants will be in good health so that they are feeling well and able to participate in the study. Participants will not be excluded if they are experiencing minor illness symptoms.
We will not exclude pregnant women who are otherwise eligible for the study, because they may benefit from our interventions and our interventions pose no additional risk to pregnant women relative to the general population. We will include minors aged 15-17 if they are receiving care in the general ART clinic because they may also benefit from our interventions; their participation will require parent/guardian consent and participant assent.
Research assistants will recruit participants from facilities on ART clinic days, working with facility HCWs to identify potentially eligible participants and conducting screening, consent, eligibility, and baseline survey procedures during waiting time or after the facility visit has concluded.
Interventions: Our intervention package includes three components:
- Enhanced counseling: at facilities supported by Partners in Hope, routine care counselling is offered to clients including those initiating and re-initiating care, and covers topics such as HIV basics, disclosure, and adherence. We will be training counselors (PIH Treatment Supporters) to provide intervention counselling on mobility topics including how to prepare for travel and options for obtaining a refill while traveling.
- Hotline: clients and HCWs at intervention facilities will receive information about a toll-free "hotline" staffed by a treatment supporter trained in mobility-related topics. The staffer will offer advice and coordination to support mobile clients and HCWs caring for them. This hotline is not part of standard of care; however, the hotline staff will provide assistance to any caller, regardless of whether they are enrolled participants or working in an intervention facility or not.
- Training on MMD: in an effort to increase rates of MMD offered to mobile clients, we will conduct a training for HCWs at intervention facilities on the benefits of MMD especially for mobile clients. The MMD prescribing guidelines will be aligned with routine care and national ART guidelines, but this additional training on the benefits of MMD and its applicability to mobility will be only offered at intervention facilities.
Research procedures:
Baseline survey: All enrolled participants will complete a baseline survey including modules on sociodemographic characteristics and economic indicators, ART and other health history, ART knowledge, HIV stigma and disclosure status, mobility history and patterns, and other risk factors for treatment interruption including depression and alcohol use.
Implementation data: We will collect data on the implementation of the intervention, including counselling recordings, counselling progress notes, a register of calls to the hotline and call recordings, and facility-level data on MMD.
Medical chart reviews: We will conduct medical chart reviews to determine ART retention outcomes and exposure to MMD for all enrolled participants.
Follow-up survey: For all participants with chart-review evidence of treatment interruption and a subset of matched controls, we will conduct community tracing to administer a follow-up survey including updated socioeconomic and ART risk factor characteristics, verification of chart review outcomes, satisfaction with services and interventions, adverse events, and mobility during trial.
IDIs: We will conduct in-depth interviews with a subset of participants to assess intervention acceptability.
FGDs: We will conduct focus group discussions with healthcare workers to assess intervention acceptability and feasibility.
- Conditions
- HIV
- Being tested
- REMIT intervention package
- Keywords
- mobility, antiretroviral therapy, HIV treatment interruption, ART retention, sub-Saharan Africa, Malawi, ART interruption
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
REMIT intervention packageBehavioural
Intervention package includes three components:
- Enhanced counseling: Counselors (PIH Treatment Supporters) will be trained to provide intervention counseling on mobility topics including how to prepare for travel and options for obtaining a refill while traveling.
- Hotline: clients and HCWs at intervention facilities will receive information about a toll-free "hotline" staffed by a treatment supporter trained in mobility-related topics. The staffer will offer advice and coordination to support mobile clients and HCWs caring for them.
- Training on MMD: HCWs at intervention facilities will be trained on the benefits of MMD especially for mobile clients. The MMD prescribing guidelines will be aligned with routine care and national ART guidelines, but this additional training on the benefits of MMD and its applicability to mobility will be only offered at intervention facilities.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Half of facilities will be randomized to intervention status and will receive the full package of interventions, including training on mobility-specific counseling for counsellors, access to a toll-free hotline for clients and healthcare workers, and training on multi-month dispensing for providers. Receives: Behavioral: REMIT intervention package |
| Control | No intervention | Half of facilities will be randomized to control status and will administer standard of care with no additional interventions offered. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Acceptability of REMIT intervention package
To assess acceptability, we will analyse qualitative data from participant IDIs and HCW FGDs. We will code data from all IDIs and FGDs in Atlas.ti using inductive and deductive codes. Coded text will be analysed using grounded theory and guided by Human Centered Design principles.
Measured: From day of intervention launch (healthcare workers) or enrollment (clients) to 6 months after final participant is enrolled
Feasibility of REMIT intervention package
To assess feasibility, we will analyse qualitative data from participant IDIs and HCW FGDs. We will code data from all IDIs and FGDs in Atlas.ti using inductive and deductive codes. Coded text will be analysed using grounded theory and guided by Human Centered Design principles. We will also review process implementation data, such as counselling recordings (fidelity of implementation and quality of counselling), the hotline register and recordings (number of calls, fidelity of implementation, and quality of counselling), and rates of MMD (compared between control and intervention facilities to assess the effectiveness of our MMD training, a component of fidelity of implementation).
Measured: From day of intervention launch (healthcare workers) or enrollment (clients) to 6 months after final participant is enrolled
Secondary outcomes (1)
Preliminary estimate of efficacy
We will use medical chart reviews and follow-up tracing surveys to determine rates of interruption in treatment (IIT, defined as missing an ART refill appointment by >28 days; of note, obtaining an emergency refill at another facility within 28 days of missing the appointment at a home facility will not be considered an IIT) among all participants.
Measured: From day of enrollment to 6 months after enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jan 2026
- Study start18 Dec 2025
- Primary completionFeb 2027 (estimated)
- Study completionFeb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIVStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Collaborators
- Partners in Hope, Inc., National Institute of Mental Health (NIMH)
- Responsible party
- Principal investigator, Marguerite Thorp, MD, MPA/ID, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07329166
- Sponsor's protocol ID
- K01MH138243
- Other IDs
- K01MH138243
- Acronym
- REMIT
- Status last verified
- Jan 2026
- First submitted
- 8 Jan 2026
- Last updated
- 9 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Fully de-identified data (including baseline surveys conducted at enrollment, medical chart reviews, endline surveys conducted after 6-month follow-up, and summaries of in-depth interviews and focus group discussions), will be uploaded to the NIMH Data Archive.
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reducing Mobility-associated Interruption in HIV Treatment in Malawi (REMIT): Pilot Trial to Assess Acceptability and Feasibility of a Mobility-specific Intervention Package
- ClinicalTrials.gov ID
- NCT07329166
- Acronym / sponsor ID
- REMIT / K01MH138243
- Conditions
- HIV
- Keywords
- mobility, antiretroviral therapy, HIV treatment interruption, ART retention, sub-Saharan Africa, Malawi, ART interruption
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Collaborators
- Partners in Hope, Inc., National Institute of Mental Health (NIMH)
- Study start
- 18 Dec 2025 (actual)
- Primary completion
- Feb 2027 (estimated)
- Study completion
- Feb 2027 (estimated)
- First posted
- 9 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this pilot clinical trial is to assess the feasibility and acceptability of an intervention package designed to reduce mobility-associated interruptions in HIV treatment in people living with HIV in Malawi who are initiating or returning to antiretroviral treatment (ART) after interruption. The main questions it aims to answer are:
- Is the intervention acceptable to healthcare workers and ART clients?
- Is the intervention feasible in the context of Malawi's health system, and what are the major operational challenges, resource requirements, and implementation barriers?
In addition, researchers will compare HIV treatment outcomes (specifically ART retention rates) between intervention and control groups to establish a preliminary estimate of the intervention's efficacy.
Participants will complete a survey on the day of enrollment and some participants will complete an in-depth interview and/or a survey after completion of the 6-month follow-up period. Facilities assigned to the intervention group will receive the full package of interventions (training on mobility-specific counseling for counsellors, access to a toll-free hotline for clients and healthcare workers, and training on multi-month dispensing for providers), while facilities assigned to the control group will provide standard of care.
Detailed description
RATIONALE FOR RESEARCH: While Malawi has made tremendous progress towards ending the HIV epidemic - nearly reaching UNAIDS' 95-95-95 target goals (95% of people living with HIV know their status, 95% of people living with HIV have initiated ART, and 95% of those on ART reach viral suppression) - certain sub-groups of people living with HIV continue to face challenges remaining in care. One key issue that perpetuates this cycle of interruption, re-initiation, and re-interruption is mobility, or temporary travel, which is the number one reason for interruption in treatment (IIT) across several of our recent studies. Mobile people living with HIV require additional interventions to stay in care and reduce IIT. In the REMIT study (Reducing Mobility-associated Interruption in HIV Treatment), we will pilot a package of interventions that have been co-created with ART clients, healthcare workers (HCWs), and community and national stakeholders. The REMIT intervention package will include: enhanced counselling at initiation or re-initiation; a toll-free line for mobile clients and HCWs; and trainings for HCWs on the benefits of multi-month dispensing (MMD).
Study design and rationale: We propose a cluster-randomized control trial to pilot these interventions at three facilities, comparing results with three control facilities (total n=6 facilities). This cluster-randomized design is appropriate for testing interventions that are offered to healthcare workers (specifically training on an enhanced counselling curriculum and the benefits of MMD); each intervention facility will receive the full intervention package.
Population: The study population will include ART clients (≥15 years) who are initiating or re-initiating ART >28 days after a missed appointment. We will enrol n=400 men and women attending ART clinic for their own care.
We will randomly select a subset of participants from intervention facilities for additional in-depth interviews. We will also conduct focus group discussions with healthcare workers working in the ART clinic at intervention facilities.
People living with HIV and health care providers will be included in the study. Participants will be in good health so that they are feeling well and able to participate in the study. Participants will not be excluded if they are experiencing minor illness symptoms.
We will not exclude pregnant women who are otherwise eligible for the study, because they may benefit from our interventions and our interventions pose no additional risk to pregnant women relative to the general population. We will include minors aged 15-17 if they are receiving care in the general ART clinic because they may also benefit from our interventions; their participation will require parent/guardian consent and participant assent.
Research assistants will recruit participants from facilities on ART clinic days, working with facility HCWs to identify potentially eligible participants and conducting screening, consent, eligibility, and baseline survey procedures during waiting time or after the facility visit has concluded.
Interventions: Our intervention package includes three components:
- Enhanced counseling: at facilities supported by Partners in Hope, routine care counselling is offered to clients including those initiating and re-initiating care, and covers topics such as HIV basics, disclosure, and adherence. We will be training counselors (PIH Treatment Supporters) to provide intervention counselling on mobility topics including how to prepare for travel and options for obtaining a refill while traveling.
- Hotline: clients and HCWs at intervention facilities will receive information about a toll-free "hotline" staffed by a treatment supporter trained in mobility-related topics. The staffer will offer advice and coordination to support mobile clients and HCWs caring for them. This hotline is not part of standard of care; however, the hotline staff will provide assistance to any caller, regardless of whether they are enrolled participants or working in an intervention facility or not.
- Training on MMD: in an effort to increase rates of MMD offered to mobile clients, we will conduct a training for HCWs at intervention facilities on the benefits of MMD especially for mobile clients. The MMD prescribing guidelines will be aligned with routine care and national ART guidelines, but this additional training on the benefits of MMD and its applicability to mobility will be only offered at intervention facilities.
Research procedures:
Baseline survey: All enrolled participants will complete a baseline survey including modules on sociodemographic characteristics and economic indicators, ART and other health history, ART knowledge, HIV stigma and disclosure status, mobility history and patterns, and other risk factors for treatment interruption including depression and alcohol use.
Implementation data: We will collect data on the implementation of the intervention, including counselling recordings, counselling progress notes, a register of calls to the hotline and call recordings, and facility-level data on MMD.
Medical chart reviews: We will conduct medical chart reviews to determine ART retention outcomes and exposure to MMD for all enrolled participants.
Follow-up survey: For all participants with chart-review evidence of treatment interruption and a subset of matched controls, we will conduct community tracing to administer a follow-up survey including updated socioeconomic and ART risk factor characteristics, verification of chart review outcomes, satisfaction with services and interventions, adverse events, and mobility during trial.
IDIs: We will conduct in-depth interviews with a subset of participants to assess intervention acceptability.
FGDs: We will conduct focus group discussions with healthcare workers to assess intervention acceptability and feasibility.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Behavioral: REMIT intervention packageHalf of facilities will be randomized to intervention status and will receive the full package of interventions, including training on mobility-specific counseling for counsellors, access to a toll-free hotline for clients and healthcare workers, and training on multi-month dispensing for providers. |
| Control | No intervention | –Half of facilities will be randomized to control status and will administer standard of care with no additional interventions offered. |
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- 15 years of age or older
- Living with HIV
- Attending ART clinic to initiate OR re-initiate care:
Key exclusion criteria (4 listed)
- Attending ART clinic on behalf of someone else (i.e. guardian)
- Attending ART clinic only to obtain emergency refill
- Attending ART clinic for a routine refill without a recent >=28 days interruption in treatment
- Transferring in to study facility without a preceding interruption in treatment of >=28 days
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| REMIT intervention packageIntervention package includes three components: 1. Enhanced counseling: Counselors (PIH Treatment Supporters) will be trained to provide intervention counseling on mobility topics including how to prepare for travel and options for obtaining a refill while traveling. 2. Hotline: clients and HCWs at intervention facilities will receive information about a toll-free "hotline" staffed by a treatment supporter trained in mobility-related topics. The staffer will offer advice and coordination to support mobile clients and HCWs caring for them. 3. Training on MMD: HCWs at intervention facilities will be trained on the benefits of MMD especially for mobile clients. The MMD prescribing guidelines will be aligned with routine care and national ART guidelines, but this additional training on the benefits of MMD and its applicability to mobility will be only offered at intervention facilities. | Behavioural | Intervention |
Primary outcome
Acceptability of REMIT intervention package
Time frame: From day of intervention launch (healthcare workers) or enrollment (clients) to 6 months after final participant is enrolled
To assess acceptability, we will analyse qualitative data from participant IDIs and HCW FGDs. We will code data from all IDIs and FGDs in Atlas.ti using inductive and deductive codes. Coded text will be analysed using grounded theory and guided by Human Centered Design principles.
Feasibility of REMIT intervention package
Time frame: From day of intervention launch (healthcare workers) or enrollment (clients) to 6 months after final participant is enrolled
To assess feasibility, we will analyse qualitative data from participant IDIs and HCW FGDs. We will code data from all IDIs and FGDs in Atlas.ti using inductive and deductive codes. Coded text will be analysed using grounded theory and guided by Human Centered Design principles. We will also review process implementation data, such as counselling recordings (fidelity of implementation and quality of counselling), the hotline register and recordings (number of calls, fidelity of implementation, and quality of counselling), and rates of MMD (compared between control and intervention facilities to assess the effectiveness of our MMD training, a component of fidelity of implementation).
1 secondary outcome
Preliminary estimate of efficacy
Time frame: From day of enrollment to 6 months after enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2026.
- Individual participant dataSharing planned: Yes. Fully de-identified data (including baseline surveys conducted at enrollment, medical chart reviews, endline surveys conducted after 6-month follow-up, and summaries of in-depth interviews and focus group discussions), will be uploaded to the NIMH Data Archive.
Related trials for HIV
RecruitingPhase 2
Evaluating the Safety and Immunogenicity of MTBVAC
HIV I Infection, Tuberculosis
Active, not recruiting
Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men
HIV Infections, STI
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Not yet recruiting
PNF RCT to Decrease Alcohol Use and Increase HIV Prevention
HIV (Human Immunodeficiency Virus), Alcohol Misuse
RecruitingObservational study
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
HIV, Immunodeficiencies
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing REMIT intervention package in people with HIV, run by University of California, Los Angeles at 1 site in Malawi.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malawi. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marguerite Thorp, MD, MPA/ID ((310) 267-5844, mthorp@mednet.ucla.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Acceptability of REMIT intervention package (time frame: From day of intervention launch (healthcare workers) or enrollment (clients) to 6 months after final participant is enrolled). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2026; AzTrials last refreshed its copy on 31 Oct 2026.